The U.S. Food and Drug Administration said on Friday it has approved Sanofi's blood cancer drug, Sarclisa, which can be given under the skin through a wearable injector, offering multiple ...
Rather than forking over nearly $100,000 on traditional liposuction, under the supervision of a medical expert, the ...
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous urticaria (CSU). This ...
Dupixent is the first biologic approved for chronic spontaneous urticaria in patients as young as 2 years of age. The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® ...
Normally on Big Pharma earnings calls, execs are eager to talk up their new launches and tout blockbuster expectations. But during Sanofi’s first-quarter presentation, a patent defense took center ...
Sanofi (SNY) and Regeneron’s (REGN) Dupixent was approved in the U.S. as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria, the companies said on Wednesday ...
About a decade ago, a group of competitive CrossFitters in Charleston, South Carolina, went looking for ways to improve their athletic performance without taking steroids. At the time, members of the ...
Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is better than Dupixent.
TARRYTOWN, N.Y. and PARIS, March 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan ...
Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis (65%), asthma (20%), and CRSwNP (10%) as core indications; each faces varying competitive pressures. Revenue projections for ...
This article is a transcript and publication of the slides from my YouTube video. The content is created for the purpose of education and information provision for pharmacists. While the content is ...
Dupixent is a prescription medication that can help manage chronic inflammatory conditions in children, such as eczema, asthma, and eosinophilic esophagitis. It can be exhausting for a child to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results